Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue Donors | 7 | 2021 | 152 | 3.020 |
Why?
|
| Organ Transplantation | 9 | 2024 | 54 | 2.640 |
Why?
|
| Hepatitis C | 5 | 2021 | 151 | 1.840 |
Why?
|
| Tissue and Organ Procurement | 5 | 2021 | 43 | 1.770 |
Why?
|
| Hepacivirus | 3 | 2020 | 141 | 1.580 |
Why?
|
| Hepatitis B | 4 | 2020 | 32 | 1.560 |
Why?
|
| Hepatitis B virus | 4 | 2020 | 15 | 1.540 |
Why?
|
| Transplant Recipients | 6 | 2024 | 35 | 1.440 |
Why?
|
| Liver Transplantation | 4 | 2021 | 215 | 1.320 |
Why?
|
| HIV | 2 | 2020 | 70 | 0.780 |
Why?
|
| Serologic Tests | 2 | 2020 | 37 | 0.730 |
Why?
|
| Donor Selection | 2 | 2018 | 17 | 0.610 |
Why?
|
| Mass Screening | 3 | 2020 | 690 | 0.590 |
Why?
|
| Communicable Disease Control | 1 | 2018 | 42 | 0.580 |
Why?
|
| Immunization | 1 | 2018 | 131 | 0.570 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2018 | 28 | 0.570 |
Why?
|
| Allografts | 1 | 2017 | 46 | 0.530 |
Why?
|
| Vaccines | 1 | 2018 | 96 | 0.530 |
Why?
|
| HIV Infections | 3 | 2020 | 967 | 0.530 |
Why?
|
| Treponema pallidum | 1 | 2015 | 5 | 0.470 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2015 | 5 | 0.470 |
Why?
|
| Syphilis | 1 | 2015 | 25 | 0.450 |
Why?
|
| Antiviral Agents | 1 | 2017 | 322 | 0.430 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2024 | 16 | 0.420 |
Why?
|
| Lip Diseases | 1 | 2012 | 1 | 0.390 |
Why?
|
| Coccidioidomycosis | 1 | 2012 | 11 | 0.380 |
Why?
|
| HIV-1 | 1 | 2018 | 721 | 0.380 |
Why?
|
| Ulcer | 1 | 2012 | 13 | 0.380 |
Why?
|
| Humans | 24 | 2024 | 63283 | 0.330 |
Why?
|
| Antifungal Agents | 3 | 2023 | 127 | 0.300 |
Why?
|
| Middle Aged | 9 | 2024 | 17535 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 784 | 0.260 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 107 | 0.260 |
Why?
|
| Young Adult | 4 | 2022 | 4683 | 0.240 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 319 | 0.220 |
Why?
|
| Adult | 6 | 2024 | 16771 | 0.200 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 2675 | 0.200 |
Why?
|
| United States | 5 | 2021 | 7828 | 0.200 |
Why?
|
| Tuberculosis | 2 | 2019 | 295 | 0.190 |
Why?
|
| Legionella | 2 | 2012 | 3 | 0.190 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5647 | 0.180 |
Why?
|
| Hepatitis A | 1 | 2020 | 8 | 0.180 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2020 | 6 | 0.170 |
Why?
|
| Hepatitis B Antibodies | 1 | 2020 | 9 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 24 | 0.170 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 18 | 0.170 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.170 |
Why?
|
| Child | 4 | 2023 | 4522 | 0.170 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 11 | 0.170 |
Why?
|
| Candida | 1 | 2020 | 39 | 0.170 |
Why?
|
| Aged | 5 | 2022 | 14384 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 115 | 0.160 |
Why?
|
| Advisory Committees | 1 | 2020 | 112 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 297 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 203 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 736 | 0.160 |
Why?
|
| Male | 8 | 2024 | 29799 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6627 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 363 | 0.150 |
Why?
|
| Cadaver | 1 | 2018 | 128 | 0.140 |
Why?
|
| Communicable Diseases | 1 | 2018 | 90 | 0.140 |
Why?
|
| Risk Factors | 4 | 2024 | 5338 | 0.140 |
Why?
|
| Simeprevir | 1 | 2017 | 5 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2017 | 17 | 0.130 |
Why?
|
| Adolescent | 3 | 2018 | 6238 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2020 | 406 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2018 | 232 | 0.130 |
Why?
|
| Klebsiella pneumoniae | 1 | 2017 | 28 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2021 | 3280 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 24 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2019 | 406 | 0.130 |
Why?
|
| Critical Care | 1 | 2020 | 397 | 0.130 |
Why?
|
| Nausea | 1 | 2017 | 111 | 0.130 |
Why?
|
| Phylogeny | 2 | 2021 | 376 | 0.130 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2015 | 1 | 0.120 |
Why?
|
| Female | 7 | 2024 | 32776 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 463 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 517 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2017 | 276 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 489 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2018 | 1988 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1084 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 349 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2015 | 78 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 5443 | 0.110 |
Why?
|
| Intestines | 1 | 2015 | 167 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2015 | 286 | 0.110 |
Why?
|
| Immunosuppressive Agents | 3 | 2024 | 377 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1355 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2020 | 1304 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 1649 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 863 | 0.100 |
Why?
|
| Coccidioides | 1 | 2012 | 10 | 0.100 |
Why?
|
| Fluconazole | 1 | 2012 | 13 | 0.100 |
Why?
|
| Pancreas Transplantation | 1 | 2012 | 20 | 0.100 |
Why?
|
| Amphotericin B | 1 | 2012 | 23 | 0.100 |
Why?
|
| Transplantation | 1 | 2012 | 11 | 0.100 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 37 | 0.090 |
Why?
|
| Latent Tuberculosis | 1 | 2012 | 23 | 0.090 |
Why?
|
| Legionellosis | 1 | 2011 | 2 | 0.090 |
Why?
|
| Endocarditis | 1 | 2012 | 29 | 0.090 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 82 | 0.090 |
Why?
|
| Endocarditis, Bacterial | 1 | 2011 | 36 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2024 | 1121 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2018 | 801 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1649 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 694 | 0.080 |
Why?
|
| Aortic Valve | 1 | 2012 | 190 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 621 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 1750 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2023 | 8 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2012 | 87 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2021 | 65 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2021 | 68 | 0.040 |
Why?
|
| DNA, Bacterial | 2 | 2012 | 265 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 413 | 0.040 |
Why?
|
| New England | 1 | 2020 | 273 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 313 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 325 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 672 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 1990 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 155 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 82 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 108 | 0.030 |
Why?
|
| Time Factors | 1 | 2024 | 3757 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1375 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 376 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2018 | 136 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 98 | 0.030 |
Why?
|
| Curriculum | 1 | 2018 | 591 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 444 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 972 | 0.020 |
Why?
|
| Transplants | 1 | 2012 | 9 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2012 | 12 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2012 | 41 | 0.020 |
Why?
|
| Base Composition | 1 | 2012 | 30 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2012 | 98 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 31 | 0.020 |
Why?
|
| Consensus | 1 | 2012 | 228 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2012 | 200 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 1613 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 766 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 10827 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 20634 | 0.010 |
Why?
|
Theodoropoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(144)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(16)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_